211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
487 articles about Daiichi Sankyo
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer
Interim DESTINY-Lung01 research data from the HER2 overexpressing metastatic non-small cell lung cancer (NSCLC) cohort of ENHERTU ® will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR
A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with ...
Longer follow-up research data for ENHERTU ® based on DESTINY-Breast01, including updated duration of response, progression-free survival, an 18-month landmark analysis of overall survival and longer-term safety profile to be highlighted New data from expansion cohorts of phase 1/2 study of patritumab deruxtecan in patients with HR positive, HER2 negative metastatic breast cancer with varying levels of HER3 expression or patients with HER3 high trip
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer
Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses
American Regent, Inc., a Daiichi Sankyo Group company, announced that Ken Keller, currently serving as the company's President and CEO, is transitioning to a new role as the Global Head of Oncology Business at Daiichi Sankyo, Inc. effective April 1, 2021.
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
Only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting
ENHERTU (fam-trastuzumab deruxtecan-nxki) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer
Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting
BioInvent International AB announces that it will receive a €2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant directed antibody.
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
First-in-human phase 1 study to evaluate DS-1055 as a new type of immune intervention for patients with relapsed/refractory advanced or metastatic solid tumors
October is Breast Cancer Awareness month, and Daiichi Sankyo is aiming to raise awareness about one of the most common forms of cancer across the globe.
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020
HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan
GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.da
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer Phase 2 study to evaluate patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, in previously treated patients with HER3 expressing advanced/metastatic colorectal cancer Initiation of third clinical study of patritumab deruxtecan demonstrates the commitment of Daiichi Sankyo to evaluate targe
AnHeart Therapeutics, Co., Ltd., a clinical stage oncology company focused on underserved patients in global markets, has through its subsidiary AnHeart Therapeutics Inc. entered into license agreements with Daiichi Sankyo Company, Limited to acquire rights to two novel clinical stage oncology candidates.
Privately-held Rain Therapeutics closed a $63 million Series B financing round that will be used to advance the company’s pipeline of targeted cancer therapies, including RAIN-32, its recently acquired asset from Daiichi Sankyo.
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and TAGRISSO (osimertinib), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients wi
SIT Laboratorio Farmaceutico, a company of DESMA HC Group, Acquires LOPRESSOR®, ICAZ® and MIOREL® from Daiichi Sankyo France
Daiichi Sankyo France /(hereafter, Daiichi Sankyo) and SIT Laboratorio Farmaceutico (DESMA HC Group) are pleased to announce the acquisition of LOPRESSOR®, ICAZ® and MIOREL® by SIT Laboratorio Farmaceutico from Daiichi Sankyo France, effective from 30 th June 2020 .
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in phase 1 clinical development for non-small cell lung cancer and triple negative breast cancer.